These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2260613)

  • 1. Recombinant human erythropoietin: physiology, pathophysiology of anemia in renal failure, and economic aspects related to dosing.
    Besarab A
    Am J Nephrol; 1990; 10 Suppl 2():2-6. PubMed ID: 2260613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anemia of renal failure. Use of erythropoietin.
    Humphries JE
    Med Clin North Am; 1992 May; 76(3):711-25. PubMed ID: 1578966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin and the anemia of chronic diseases.
    De Marchi S; Pirisi M; Ferraccioli GF
    Clin Exp Rheumatol; 1993; 11(4):429-44. PubMed ID: 8403591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to recombinant human erythropoietin in hemodialysis patients.
    Drüeke TB
    Am J Nephrol; 1990; 10 Suppl 2():34-9. PubMed ID: 2260616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric uses of recombinant human erythropoietin: the outlook in 1991.
    Alexander SR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):42-53. PubMed ID: 1928079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The practical aspects of therapy with rHuEPO.
    Spinowitz B
    Am J Nephrol; 1990; 10 Suppl 2():24-8. PubMed ID: 2260614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients.
    Lui SF; Wong KC; Li PK; Lai KN
    Am J Nephrol; 1992; 12(1-2):55-60. PubMed ID: 1415366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Lui SF; Law CB; Ting SM; Li P; Lai KN
    Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of purified recombinant human erythropoietin on anemia in rats with experimental renal failure induced by five-sixth nephrectomy.
    Kawamura A; Higuchi M; Imai N; Kawaguchi T; Ogura Y
    Biotherapy; 1990; 2(1):77-85. PubMed ID: 2400629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical approach to initiation of recombinant human erythropoietin therapy and prevention and management of adverse effects.
    Abraham PA
    Am J Nephrol; 1990; 10 Suppl 2():7-14. PubMed ID: 2260619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study.
    Cheng IK; Cy C; Chan MK; Yu L; Fang GX; Wei D
    Clin Nephrol; 1991 May; 35(5):207-12. PubMed ID: 1855328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human erythropoietin: implications for nephrology.
    Eschbach JW; Adamson JW
    Am J Kidney Dis; 1988 Mar; 11(3):203-9. PubMed ID: 3278599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correction of anemia in chronic kidney failure with lyophilized recombinant human erythropoietin using a subcutaneous approach].
    Amar M; Cendoroglo Neto M; Canziani ME; Nadaletto MA; Ajzen H; Draibe SA
    Rev Assoc Med Bras (1992); 1994; 40(2):101-7. PubMed ID: 7820145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of human recombinant erythropoietin (rHuEPO) for treatment of anemia in patients with chronic kidney failure who don't require additional dialysis therapy].
    Wiecek A
    Przegl Lek; 1995; 52(3):93-4. PubMed ID: 7644683
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of recombinant human erythropoietin (rHuEpo) in humans.
    Adamson JW; Eschbach JW
    Cancer Surv; 1990; 9(1):157-67. PubMed ID: 2276112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of low doses of recombinant human erythropoietin on renal anemia in predialysis patients with chronic renal failure].
    Zheng FL; Bi ZQ; Li RS
    Zhonghua Nei Ke Za Zhi; 1993 Jul; 32(7):440-3. PubMed ID: 8275819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients.
    Yamazaki C; Watanabe Y; Sakamoto N
    Nihon Jinzo Gakkai Shi; 1993 Nov; 35(11):1233-42. PubMed ID: 8139135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy.
    Eschbach JW; Adamson JW
    Kidney Int Suppl; 1999 Mar; 69():S35-43. PubMed ID: 10084284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.